CancerLinQ®, originally established by the American Society of Clinical Oncology (ASCO®) and now operated by ConcertAI, introduces three groundbreaking initiatives at the 2024 ASCO Annual Meeting, integrated into the widely used SmartLinQ™ application:
1. **ASCO Certified™**: ASCO Certified, initiated in October 2023, incorporates ASCO’s quality measures into SmartLinQ. It simplifies quality assessment and aligns with oncology medical home standards, enhancing patient-centered practice transformation. CancerLinQ automates ASCO Certified solutions, streamlining quality measurement reporting for practices utilizing Elsevier ClinicalPath™.
2. **RxLinQ™**: A precision medicine feature, RxLinQ identifies patients eligible for newly approved therapies. It reduces administrative burdens by automating patient eligibility assessment, enhancing outcomes through partial matches, and improving population health by matching both new and existing patients to appropriate therapies.
3. **TriaLinQ™**: Designed to simplify clinical trial enrollment, TriaLinQ streamlines patient-to-trial matching within SmartLinQ. It automates manual tasks, ensures diverse patient inclusion, and enhances precision in patient eligibility reviews, thereby increasing patient treatment options and expanding access to clinical trials.
These initiatives reflect CancerLinQ’s commitment to supporting oncology care providers amidst rapid advancements in the field. Louis Culot, CancerLinQ’s General Manager, emphasizes the importance of a learning network approach leveraging clinical AI and informatics to support diverse oncology centers.
CancerLinQ’s transition to a ConcertAI initiative in late 2023 established a long-term cooperation agreement with ASCO, ensuring continued delivery of quality solutions and Software as a Service (SaaS) technologies to the oncology community. By harnessing data from nearly 7 million patient records, CancerLinQ aims to improve patient care quality and accelerate research outcomes, ultimately advancing evidence-based oncology care.